Remove issue value
article thumbnail

Opinion: Patent buyouts could spur vital innovation in antibiotics, vaccines, and other medical fields

STAT

But this debate sidesteps the larger issue of whether the patent system delivers the value it should in health care. The real dispute centers on whether the prospect of price negotiations will reduce future innovation by shrinking the expected future profits for patented drugs.

Vaccines 283
article thumbnail

STAT+: What’s behind the recent surge in Apellis’ stock price? Growing confidence in the safety of its eye treatment

STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

246
246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: How a cash-prize system that phases out patents may lower drug prices

STAT

They argue the government may not always have the financial or budgetary wherewithal to fund prizes, awards may be vulnerable to political influence, and sometimes the expertise may be lacking to establishing the correct value in order to award an appropriate prize. This is an edited version of our conversation.

article thumbnail

Opinion: The second age of psychedelic therapies for mental health

STAT

Psychedelics like psilocybin and ketamine are being touted as the next generation of treatment for depression, anxiety, and other mental health issues. But it’s not like flipping a switch: These therapies involve a novel administration paradigm, acceptance by regulatory bodies, and public appreciation of their unique medicinal value.

253
253
article thumbnail

Cold Chain Solutions Supplement: Further Exploration of Pharma’s Temperature-Controlled Sector

Pharmaceutical Commerce

Post LogiPharma, the editors of Pharmaceutical Commerce examine the trends and highlights that came out of the conference, specifically surrounding the cold chain solutions segment.

article thumbnail

Pharma's ESG Equation: Materiality and Strategy are Key

PharmExec

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

93
article thumbnail

Navigating the Job Interview: How to Answer the Question, “Why Are You Changing Jobs?”

LifeProNow

Address Issues Respectfully and Positively Sometimes, the reasons for changing jobs are less about seeking opportunities and more about addressing challenges or issues in your current position. I’m excited about the opportunity to contribute my skills and experiences to a team that shares my values and vision.

100
100